UNIGE document Scientific Article
previous document  unige:120077  next document
add to browser collection
Title

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients

Authors
Grandjean Hallez, Nicole
show hidden authors show all authors [1 - 21]
Published in Neuro-Oncology. 2019
Abstract Peptide vaccines offer the opportunity to elicit glioma-specific T cells with tumor killing ability. Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted with poly-ICLC in HLA-A2 + glioma patients.
Identifiers
PMID: 30753611
Full text
Article (Accepted version) (1 MB) - public document Free access
Article (Published version) (4.2 MB) - public document Free access
Structures
Research groups La Sclérose en plaques (908)
Immunobiologie des tumeurs du cerveau (669)
Immunothérapie des cancers (42)
Optimisations des techniques avancés en neuroimagerie (985)
Citation
(ISO format)
MIGLIORINI, Denis et al. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. In: Neuro-Oncology, 2019. doi: 10.1093/neuonc/noz040 https://archive-ouverte.unige.ch/unige:120077

320 hits

193 downloads

Update

Deposited on : 2019-06-26

Export document
Format :
Citation style :